unknown
Stage
1
Investors
About
YourChoice Therapeutics is developing YCT-529, a selective retinoic acid receptor-alpha antagonist as an oral, non-hormonal male contraceptive currently in Phase 2 clinical trials.
Explore YourChoice Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.